www.scoop.co.nz ·
Public Hospitals to Save Millions on Drug Eluting Stents
Topic context
This topic has been covered 267410 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedThis is a single-country (New Zealand) public procurement agreement affecting drug-eluting stents, a medical device. The channel is cost reduction for public hospitals via a negotiated supply contract. No scarcity or demand spike; it's a routine supplier agreement with modest savings. The impact is limited to New Zealand's public hospital system and Medtronic's local revenue.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Pharmac secured agreement with Medtronic New Zealand for drug-eluting stents supply to public hospitals.
- Estimated savings of $1.2 million annually.
- Medtronic to supply 65% of stents for three years starting June 1, 2026.
- Approximately 10,000 stents used per year in NZ public hospitals.
- Transition period from June 1 to September 30, 2026 for training and adaptation.
Drug-eluting stents' impact remains flat mid-term; negligible savings confined to NZ over 6-12 months.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- GLOBAL_HEALTHCAREmid
- GLOBAL_HEALTHCAREshort
- MEDICAL_DEVICESmid
- MEDICAL_DEVICESshort
Related stories
finance.yahoo.com
Ncmi Q1 2026 Earnings Transcript
economictimes.indiatimes.com
Zydus Lifesciences Shares Jump 6 on Buyback Buzz Co Announces 166 Mn Assertio Acquisition
finance.yahoo.com
Transcript Valneva Q1 2026 Earnings
finance.yahoo.com
Aytu Aytu Q3 2026 Earnings
economictimes.indiatimes.com